Vyome Holdings Inc (HIND)

Dec 15, 2025

Vyome inches towards US FDA approval to enter $1B worth malignant fungating wound market - BioSpectrum India

Dec 15, 2025

Dec 09, 2025

Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints - MSN

Dec 09, 2025

Dec 09, 2025

Check Out Vyome Holdings Inc (HIND)’s Trade Data Rather Than the Analysts’ Views - setenews.com

Dec 09, 2025

Dec 09, 2025

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval - BioSpace

Dec 09, 2025

Dec 08, 2025

Vyome stock soars after malodor treatment shows positive results - Investing.com

Dec 08, 2025

Dec 08, 2025

Vyome stock soars after malodor treatment shows positive results By Investing.com - Investing.com UK

Dec 08, 2025

Dec 08, 2025

Vyome reports positive final Phase 2 results for VT-1953, plans to advance into pivotal study for FDA approval - marketscreener.com

Dec 08, 2025

Dec 05, 2025

HIND Stock Price and Chart — NASDAQ:HIND - TradingView

Dec 05, 2025

Dec 05, 2025

Vyome Holdings (HIND) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 05, 2025

Dec 02, 2025

JOLLY MOHANJIT Insider Trades - Nasdaq

Dec 02, 2025

Dec 01, 2025

Vyome Holdings, Inc. (HIND) Recent Insider Transactions - Yahoo! Finance Canada

Dec 01, 2025

Nov 28, 2025

Vyome Holdings, Inc. (HIND) recent insider transactions - Yahoo Finance UK

Nov 28, 2025

Nov 28, 2025

Vyome Holdings, Inc. (HIND) Profit Margin (Quarterly) - Zacks Investment Research

Nov 28, 2025

Nov 26, 2025

Vyome Holdings files prospectus related to resale of 610,185 shares of common stock by selling stockholders - marketscreener.com

Nov 26, 2025

Nov 26, 2025

Vyome Holdings Files Prospectus Related To Resale Of 610,185 Shares Of Common Stock By Selling Stockholders - TradingView

Nov 26, 2025

Nov 26, 2025

Vyome Holdings Inc. Reports Post-Merger Financials - MSN

Nov 26, 2025

Nov 25, 2025

Vyome taps Dr. Bardia as senior medical advisor for wound treatment - Investing.com Nigeria

Nov 25, 2025

Nov 25, 2025

Vyome Appoints Dr. Aditya Bardia as Senior Medical Advisor - citybiz

Nov 25, 2025

Nov 25, 2025

Vyome taps Dr. Bardia as senior medical advisor for wound treatment By Investing.com - Investing.com South Africa

Nov 25, 2025

Nov 25, 2025

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program - Yahoo Finance

Nov 25, 2025

Nov 20, 2025

Earnings call transcript: Vyome Holdings Q3 2025 sees strategic advancements - Investing.com Nigeria

Nov 20, 2025

Nov 18, 2025

Vyome Therapeutics2025 Latest Shareholding - Tracxn

Nov 18, 2025

Nov 18, 2025

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing - Bluefield Daily Telegraph

Nov 18, 2025

Nov 14, 2025

Vyome Holdings Inc. (HIND) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 14, 2025

Nov 14, 2025

Vyome Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener

Nov 14, 2025

Nov 12, 2025

HIND Forecast — Price Target — Prediction for 2026 - TradingView

Nov 12, 2025

Nov 11, 2025

Critical Contrast: Vyome (NASDAQ:HIND) vs. TranS1 (OTCMKTS:BAXSQ) - Defense World

Nov 11, 2025

Nov 06, 2025

Working capital per share of Vyome Holdings, Inc. – MUN:H1O - TradingView

Nov 06, 2025

Nov 05, 2025

ReShape Lifesciences (OTCMKTS:RSLSD) vs. Vyome (NASDAQ:HIND) Critical Analysis - Defense World

Nov 05, 2025

Nov 04, 2025

Vyome Holdings Announces Results of Annual Shareholder Meeting - The Joplin Globe

Nov 04, 2025

Nov 03, 2025

Contrasting ReShape Lifesciences (OTCMKTS:RSLSD) & Vyome (NASDAQ:HIND) - Defense World

Nov 03, 2025

Nov 02, 2025

Comparing Anzu Special Acquisition Corp I (NASDAQ:ANZUW) & Vyome (NASDAQ:HIND) - Defense World

Nov 02, 2025

Oct 31, 2025

Vyome Holdings Elects Directors at Annual Meeting - MSN

Oct 31, 2025

Oct 31, 2025

Vyome Holdings, Inc.Common Stock (Nasdaq:HIND) Stock Quote - Markets Financial Content

Oct 31, 2025

Oct 27, 2025

Head-To-Head Contrast: Vyome (NASDAQ:HIND) & TranS1 (OTCMKTS:BAXSQ) - Defense World

Oct 27, 2025

Oct 25, 2025

ReShape Lifesciences : trade; to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate UpdateForm 8-K/A - MarketScreener

Oct 25, 2025

Oct 17, 2025

Tincoff John M. Iii Net Worth (2025) - GuruFocus

Oct 17, 2025

Oct 16, 2025

ReShape Lifesciences (OTCMKTS:RSLSD) versus Vyome (NASDAQ:HIND) Financial Survey - Defense World

Oct 16, 2025

Oct 13, 2025

Will Vyome's Topical Gel Be The First FDA-Approved Treatment For Cancer Wounds? - RTTNews

Oct 13, 2025

Oct 12, 2025

Head-To-Head Comparison: Vyome (NASDAQ:HIND) vs. Bioventus (NASDAQ:BVS) - Defense World

Oct 12, 2025

Oct 06, 2025

Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World

Oct 06, 2025

Oct 04, 2025

Maxim Group Reaffirms “Buy” Rating for Vyome (NASDAQ:HIND) - Defense World

Oct 04, 2025

Oct 03, 2025

Vyome Holdings Acquires AI Startup Oculo, Inc. - TipRanks

Oct 03, 2025

Oct 02, 2025

HIND Analyst Forecasts - Quiver Quantitative

Oct 02, 2025

Sep 30, 2025

Vyome Holdings acquires Oculo Health - Medical Buyer

Sep 30, 2025

Sep 30, 2025

Vyome Holdings Acquires MIT Spinout Oculo Health, Launches AI Psychiatrist Business Unit - Sahyadri Startups

Sep 30, 2025

Sep 29, 2025

Vyome Holdings Acquires MIT AI Spinout Oculo Health - citybiz

Sep 29, 2025